Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.71 USD | -3.39% | +0.54% | -60.15% |
Financials (USD)
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 314M |
---|---|---|---|---|---|
Net income 2024 * | -40M | Net income 2025 * | -55M | EV / Sales 2024 * | - |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-7.73
x | P/E ratio 2025 * |
-5.8
x | Employees | 40 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 96.95% |
Latest transcript on Anavex Life Sciences Corp.
1 day | -3.39% | ||
1 week | +0.54% | ||
Current month | +1.64% | ||
1 month | -15.49% | ||
3 months | -34.80% | ||
6 months | -37.86% | ||
Current year | -60.15% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 58 | 13-07-04 | |
Sandra Boenisch
DFI | Director of Finance/CFO | 43 | 15-09-30 |
Edward Hammond
CTO | Chief Tech/Sci/R&D Officer | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 58 | 13-07-04 | |
Tom Skarpelos
FOU | Founder | 57 | 04-01-22 |
Jiong Ma
CHM | Chairman | 60 | 21-05-24 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.08% | 0 M€ | 0.00% | - | |
0.07% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-08 | 3.71 | -3.39% | 1,010,038 |
24-05-07 | 3.84 | 0.00% | 876,789 |
24-05-06 | 3.84 | -0.26% | 673,073 |
24-05-03 | 3.85 | +2.39% | 872,311 |
24-05-02 | 3.76 | +1.90% | 743,329 |
Delayed Quote Nasdaq, May 08, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-60.15% | 314M | |
+2.93% | 108B | |
-0.90% | 23.46B | |
-14.60% | 21.72B | |
-7.05% | 18.64B | |
-38.55% | 17.45B | |
-8.83% | 17.19B | |
+5.51% | 13.99B | |
+37.49% | 12.53B | |
+329.39% | 8.81B |
- Stock Market
- Equities
- AVXL Stock